Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS248 in Advanced Solid Tumors
NCT05759234Phase 1Unknown
- Sponsor
- Hanhui Pharmaceutical
- Start
- Nov 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of HS248 in solid tumor, sponsored by Hanhui Pharmaceutical. Primary endpoints: Safety and Tolerability up to 2 years and Maximum Tolerated Dose / Recommended Phase II Dose up to 2 years. Status: unknown.
02
Drugs
HS248
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05759234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05759234.